Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility

Background: BRAF/MEK inhibitors (BRAFi/MEKi) improve outcome in patients with BRAF-mutated metastatic melanoma but are associated with cardiotoxicity, leading to a decline in left ventricular ejection fraction (LVEF). This study aimed to evaluate the incidence, timeline, risk factors, and reversibil...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jonas K. Oddershede, Ida K. Meklenborg, Lars Bastholt, Louise M. Guldbrandt, Henrik Schmidt, Rasmus B. Friis
Format:	Artigo
Idioma:	Inglês
Publicat:	Medical Journals Sweden 2025-04-01
Col·lecció:	Acta Oncologica
Matèries:	BRAF/MEK inhibition cardiotoxicity malignant melanoma echocardiography multigated acquisition scan oncocardiology
Accés en línia:	https://medicaljournalssweden.se/actaoncologica/article/view/42567
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!